Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

$Abbott's fractional flow reserve (FFR) system. #TCT #TCT21 #FAME3$

News | FFR Technologies

FAME 3 Study Finds FFR Guided PCI Did Not Perform as Well at One-year Compared to Bypass Surgery

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation ...

November 09, 2021

The Alvimedica Cre8 Evo Cre8 polymer-free amphilimus-eluting stent

News | Stents

Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

News | FFR Technologies

QFR Technology for Advanced Coronary Artery Disease Leads to Improved Outcomes

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure ...

November 09, 2021

A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes data from of peripheral vascular interventions guided by intravascular ultrasound (IVUS) showed a 32% reduction in major adverse limb events, such as amputations, during lower extremity arterial intervention.

News | Intra-Vascular Ultrasound (IVUS)

IVUS Improved Outcomes in Largest Real-world Analysis of Lower Extremity Peripheral Vascular Interventions

November 9 2021 — A new large-scale, real-world analysis of Centers for Medicare and Medicaid Services (CMS) outcomes ...

November 09, 2021

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

The ControlRad device collimates the area of interest where the physicians are working, and reduces the dose significantly to peripheral areas in the image.

News | Radiation Dose Management

Beaumont Uses New Cardiac Cath Lab Technology to Reduce Radiation Exposure

November 5, 2021 – An FDA-approved device used during cardiac cath lab procedures cut radiation exposure for ...

November 05, 2021

Cardiac CT Given Strong Recommendation as Front-line Imaging of Chest Pain, but the American Society of Nuclear Cardiology (ASNC) did not support the guidelines.

Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

First International Chest Pain Diagnosis Guidelines Released

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

October 29, 2021

Philips, a global leader in health technology and IVUS solutions, announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions

News | Intra-Vascular Ultrasound (IVUS)

First-ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions

October 20, 2021 — Philips, a global leader in health technology and intravascular ultrasound (IVUS) solutions ...

October 20, 2021

The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.

News | Drug-Eluting Balloons

18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

October 20, 2021

the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention

News | Peripheral Artery Disease (PAD)

Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

October 20, 2021

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

A comparison between healthy artery (left) and inflamed artery (right) using perivascular fat attenuation index (FAI) mapping to detect spatial changes in perivascular fat composition induced by inflammation of the vascular wall caused by high-risk plaques.

Feature | Computed Tomography (CT)

CT Coronary Perivascular Fat Assessment Can Stratify Cardiac Risk Associated With High-Risk Plaques

October 6, 2021 — Data presented during the late-breaking science session at the European Society of Cardiology (ESC) 20 ...

October 06, 2021